Ceyhan-Birsoy, Ozge
Jayakumaran, Gowtham
Kemel, Yelena
Misyura, Maksym
Aypar, Umut
Jairam, Sowmya
Yang, Ciyu
Li, Yirong
Mehta, Nikita
Maio, Anna
Arnold, Angela
Salo-Mullen, Erin
Sheehan, Margaret
Syed, Aijazuddin
Walsh, Michael
Carlo, Maria
Robson, Mark
Offit, Kenneth
Ladanyi, Marc
Reis-Filho, Jorge S.
Stadler, Zsofia K.
Zhang, Liying
Latham, Alicia
Zehir, Ahmet
Mandelker, Diana http://orcid.org/0000-0003-4154-0567
Funding for this research was provided by:
Marie-Josée and Henry R. Kravis Center for Molecular Oncology
National Institutes of Health (NIH)/National Cancer Institute (NCI) Cancer Center (P30 CA008748)
National Institutes of Health (NIH)/National Cancer Institute (P50 CA247749 01)
Article History
Received: 8 April 2022
Accepted: 3 August 2022
First Online: 15 August 2022
Declarations
:
: All patients in the study provided written informed consent for genetic testing under an institutional review board-approved protocol (#12-245) as part of the MSK Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT; ClinicalTrials.gov identifier, NCT01775072) paired tumor-blood DNA sequencing test. All participants also provided consent to participate in the study. The study conforms to the principles of the Helsinki Declaration.
: Not applicable.
: J.S. Reis-Filho reports receiving personal/consultancy fees from Goldman Sachs, REPARE Therapeutics, Paige.AI, and Eli Lilly; membership of the scientific advisory boards of VolitionRx, REPARE Therapeutics, Paige.AI, and Personalis; membership of the Board of Directors of Grupo Oncoclinicas; and ad hoc membership of the scientific advisory boards of Roche Tissue Diagnostics, Ventana Medical Systems, Novartis, Genentech, and InVicro, outside the scope of this study. Z.K. Stadler’s immediate family member serves as a consultant in Ophthalmology for Alcon, Adverum Biotechnologies, Gyroscope Therapeutics Limited, Neurogene, and RegenexBio outside the submitted work. M.E. Robson reports grants from AstraZeneca, Merck, and Pfizer and personal fees from Change Healthcare outside the submitted work, as well as an uncompensated advisory for Artios Pharma, AstraZeneca, Daiichi Sankyo, Epic Sciences, Merck, Pfizer, Tempus Lab, and Zenith Pharma. L. Zhang reports receiving honoraria from Future Technology Research LLC, BGI, Illumina, and Roche Diagnostics Asia Pacific. L. Zhang’s family members hold a leadership position and ownership interests of Decipher Medicine. A. Zehir is currently an employee of AstraZeneca. The remaining authors declare that they have no competing interests.